This educational symposium discussed advances in blocking the renin–angiotensin–aldosterone system (RAAS) for patients with chronic systolic heart failure (HF), and the issues of managing hyperkalaemia in these patients.
Prof John McMurray introduced the session, outlining the current treatment paradigm and the challenges presented by the associated risks of hyperkalaemia. Prof Faiez Zannad discussed the under-utilisation of life-saving RAAS inhibitor (RAASi) drugs in clinical practice and the benefits to be gained for patients by optimising their use. Prof Ileana Piña reviewed current advances in pharmacological treatments for chronic HF that aim to reduce the risks of renal dysfunction and hyperkalaemia. Finally, Prof John McMurray discussed the potential of new treatment paradigms for improved outcomes in patients with chronic HF.
Please view the full content in the PDF above.